论文部分内容阅读
目的 研究抗心磷脂抗体与中青年缺血性脑血管疾病关系。方法 以酶联免疫吸附法 (ELISA)对 76例脑梗死病人 (<5 0岁 39例 ,≥ 5 0岁 37例 ) ,2 5例非缺血性脑血管疾病病人及 15例正常人的血清抗心磷脂抗体 (ACL抗体 )进行测定。结果 <5 0岁的脑梗死病人ACL抗体阳性率为 35 9% ,≥ 5 0岁的脑梗死病人ACL抗体阳性率 16 2 % ,对照组ACL抗体阳性率 7 5 %。 <5 0岁脑梗死病人的ACL抗体阳性率高于≥ 5 0岁的脑梗死病人及对照组 (P <0 0 5 )。≥ 5 0岁脑梗死病人ACL抗体阳性率与对照组无显著差异。说明临床上无任何自身免疫疾病中青年脑梗死病人与ACL抗体更密切相关。结论 ACL抗体是中青年脑血管疾病的重要危险因素 ,对中青年脑梗死病人应积极检测ACL抗体 ,提示除常规脑梗死治疗外 ,加入免疫抑制剂、血浆置换治疗有一定的积极意义。ACL抗体的检测为中青年脑血管病的一级预防提供可靠依据
Objective To study the relationship between anticardiolipin antibodies and middle-aged and young ischemic cerebrovascular diseases. Methods Seventy-six patients with cerebral infarction (39 cases <50 years old, 37 cases ≥50 years old), 25 cases of non-ischemic cerebrovascular disease and 15 cases of normal human serum were detected by enzyme-linked immunosorbent assay (ELISA) Anticardiolipin antibodies (ACL antibodies) were measured. Results The positive rate of ACL antibody in 35-year-old patients with cerebral infarction was 35 9%. The positive rate of ACL antibody in patients with cerebral infarction ≥ 50 years old was 16 2%, while the positive rate of ACL antibody in control group was 75%. The positive rate of ACL antibody in patients with cerebral infarction <50 years old was higher than that of patients with cerebral infarction ≥ 50 years old and the control group (P <0.05). The positive rate of ACL antibody in patients with cerebral infarction ≥ 50 years old had no significant difference with that of the control group. Description of the clinical absence of any autoimmune disease in young patients with cerebral infarction and ACL antibodies are more closely related. Conclusion ACL antibody is an important risk factor for middle-aged and young patients with cerebrovascular disease. Active detection of ACL antibodies in patients with middle-aged and young cerebral infarction suggests that in addition to conventional cerebral infarction, adding immunosuppressive agents and plasma exchange therapy has some positive effects. The detection of ACL antibody provides a reliable basis for primary prevention of middle cerebral artery disease